Skip to main content

Market Overview

Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic

Share:
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic

Denmark’s healthcare authority has decided to favor less expensive drugs for type 2 diabetes patients, impacting the prescription of costlier GLP-1 drugs such as Novo Nordisk’s (NYSE:NVO) Ozempic. This comes a day ahead of the company announcing its first-quarter earnings of 2024.

What Happened: The Danish Medicines Agency disclosed on Wednesday that starting from Nov. 25, patients will be prescribed less expensive drugs before resorting to GLP-1 drugs. The agency noted that in 2023, half of the new type 2 diabetes patients started their treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first.

Despite the popularity of GLP-1 drugs like Ozempic due to their weight-loss effects, the Danish Medicines Agency expects nearly half of all current GLP-1 drug users to switch to cheaper alternatives. The agency reassured that it would continue to reimburse patients for their GLP-1 drugs if the less expensive alternatives do not suffice.

See Also: AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown

Why It Matters: This decision will affect drugs like Novo Nordisk’s Ozempic and Rybelsus, and Eli Lilly’s Trulicity. The Medicines Agency has recommended the less costly alternatives on par with GLP-1 drugs.

This move comes in the wake of Sen. Bernie Sanders’ (I-Vt.) criticism of the “outrageous” prices of Ozempic. Furthermore, Americans have been swapping fast food for weight-loss drugs like Ozempic, which have quadrupled the number of prescriptions to more than 8 million last year.

However, the popularity of these drugs has also led to shortages in countries like Germany.

Price Action: Novo Nordisk’s stock closed at $128.31 on Tuesday, according to Benzinga Pro.

Read Next: 90% Of Americans Believe We Are Experiencing A Mental Health Care Crisis – Elevate Health And Wellness Is Providing Relief

Photo via Shutterstock


Engineered by Benzinga Neuro, Edited by
Pooja Rajkumari


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you.
Learn more.


 

Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: Denmark OzempicBiotech News Eurozone Health Care Markets General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com